These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6363565)

  • 21. Ceftazidime in the therapy of pseudomonal meningitis.
    Marone P; Concia E; Maserati R; Suter F; Minoli L; Andreoni M; Fiori G
    Chemioterapia; 1985 Aug; 4(4):289-92. PubMed ID: 3902257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteremia treated with cefepime or ceftazidime.
    Ratliff AR; Gentry CA; Williams RJ
    Diagn Microbiol Infect Dis; 2017 Apr; 87(4):376-381. PubMed ID: 28087171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa.
    Xipell M; Bodro M; Marco F; Losno RA; Cardozo C; Soriano A
    Int J Antimicrob Agents; 2017 Feb; 49(2):266-268. PubMed ID: 27979500
    [No Abstract]   [Full Text] [Related]  

  • 25. Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits.
    Hackbarth CJ; Chambers HF; Stella F; Shibl AM; Sande MA
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():65-9. PubMed ID: 3100492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Third-generation cephalosporins in the treatment of pneumonia due to Pseudomonas aeruginosa in guinea pigs.
    Pennington JE; Johnson CE; Platt R
    J Infect Dis; 1982 Oct; 146(4):567. PubMed ID: 6214595
    [No Abstract]   [Full Text] [Related]  

  • 27. Cephalosporins in the treatment of meningitis.
    Neu HC
    Drugs; 1987; 34 Suppl 2():135-53. PubMed ID: 3319497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftazidime in the treatment of chronic suppurative otitis media in children.
    Lautala P; Vare M; Vuorinen O; Kaar ML
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():365-7. PubMed ID: 6352646
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Monotherapy of systematic Pseudomonas aeruginosa infections with ceftazidime. The causes of therapeutic failures].
    Blaser J; Bauernfeind A; Vogt M; Lüthy R
    Dtsch Med Wochenschr; 1983 Sep; 108(35):1312-7. PubMed ID: 6411442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moxalactam therapy for gram-negative bacillary meningitis.
    Rahal JJ
    Rev Infect Dis; 1982; 4 Suppl():S606-9. PubMed ID: 6218572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomonas meningitis therapy recommendation questioned.
    Savarino SJ; Rennels MB; Drusano GL
    Pediatrics; 1989 Apr; 83(4 Pt 2):632-3. PubMed ID: 2648308
    [No Abstract]   [Full Text] [Related]  

  • 32. The treatment of bone infections with ceftazidime.
    Dutoy JP; Wauters G
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():229-33. PubMed ID: 6352624
    [No Abstract]   [Full Text] [Related]  

  • 33. [Current aspects of pseudomonas meningitis].
    Brückner O; Borner K; Hoffmann HG; Trautmann M; Collmann H
    Neurochirurgia (Stuttg); 1985 Jan; 28(1):12-6. PubMed ID: 2983254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa.
    Fantin B; Farinotti R; Thabaut A; Carbon C
    J Antimicrob Chemother; 1994 Mar; 33(3):563-9. PubMed ID: 8040120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with ceftazidime in cystic fibrosis.
    Dodge J; Zamiri I; Goodchild M; Ingram P
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():325-9. PubMed ID: 6352637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ceftazidime-related nonconvulsive status epilepticus.
    Klion AD; Kallsen J; Cowl CT; Nauseef WM
    Arch Intern Med; 1994 Mar; 154(5):586-9. PubMed ID: 8122952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with ceftazidime in urology in Japan.
    Kawamura N
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():65-70. PubMed ID: 6352657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.
    Scully BE; Neu HC
    Arch Intern Med; 1984 Jan; 144(1):57-62. PubMed ID: 6419690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftazidime in the therapy of serious Gram-negative bacillary infections.
    Pottage JC; Karakusis PH; Fliegelman RM; Levin S; Trenholme GM
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():223-8. PubMed ID: 6352623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.